Podcasts about ahns

In this episode of BackTable ENT, Dr. Tammara Watts, surgeon-scientist at Duke University, sits down with host Dr. Gopi Shah to discuss two exciting scholarship opportunities for medical students available through the American Head & Neck Society (AHNS). --- SHOW NOTES Fewer than 5% of practicing otolaryngologists identify as members of underrepresented minority groups (URM), and these scholarships directly address that disparity. Gopi and Tammara then transition to discussing the importance of diversity in otolaryngology more broadly. First, Tammara expounds on what is gained by having a workforce that includes individuals with diverse backgrounds and experiences. Through the Dr. Eddie Méndez Research Fellowship and the Myers' Family Summer Fellowship, AHNS provides unique opportunities for aspiring otolaryngologists who identify as URM to connect with future colleagues. The Research Fellowship provides $10,000 to a medical student interested in spending one year immersed in otolaryngology research. It is unique in that AHNS provides a list of mentors (with bio-sketches) that interested applicants can connect with to formulate a research plan before applying. The Myers' Family Summer Fellowship financially supports a rising MS2 or MS3 student to gain exposure in Head & Neck Surgery. Next, Tammara offers tips on cultivating successful mentor-mentee relationships, emphasizing that mentors enjoy supporting their future colleagues, and that it is easier to do so when the mentee takes initiative. Finally, Tammara shares her philosophy regarding DEI. Though otolaryngologic patients come from all walks of life, their surgeons can't always conceptualize how their experiences influence their care. By supporting URM students interested in ENT, she (along with her AHNS colleagues) are helping create a workforce that can better understand and heal. --- RESOURCES AHNS's Dr. Eddie Méndez Fellowship: https://www.ahns.info/dr-eddie-mendez-research-fellowship/ AHNS's Myers' Family Summer Fellowship in Otolaryngology: https://www.ahns.info/myers-summer-fellowship/ Dr. Tammara Watts MD, PhD's Duke University Profile: https://headnecksurgery.duke.edu/profile/tammara-lynn-watts

ASMR U REDY 2 RUMBL? This is Part B of the all audio version of Grind Time Wrestling's All Heart, No Soul event. AHNS took place February 20th, 2021 at the GTW Grindhouse in Sarasota, FL. Go to www.grindtimewrestling.com for information on the next GTW event, coming to you March 27th, 2021, March To Glory. As always, go to www.jabroniu.com to check out all the great shows the Jabroni U Podcast Network has to offer.

ASMR U REDY 2 RUMBL? This is Part A of the all audio version of Grind Time Wrestling's All Heart, No Soul event. AHNS took place February 20th, 2021 at the GTW Grindhouse in Sarasota, FL. Go to www.grindtimewrestling.com for information on the next GTW event, coming to you March 27th, 2021, March To Glory. As always, go to www.jabroniu.com to check out all the great shows the Jabroni U Podcast Network has to offer.

Gavin Setzen, MD, AAO-HNS/F Past President; Albert L. Merati, MD, AAO-HNS/F Past President; Sujana S. Chandrasekhar, MD, AAO-HNS/F Past President; Cherie-Ann Nathan, MD, President of the AHNS; Joseph K. Han, MD, President-Elect of the; and Margo K. McKenna, MD, Director, Pediatric Otolaryngology at the University of Rochester Medical Center.

Reunited with their buds, DENJA talks to the Ahns. They discuss the move to N.C., life in out there, and the Pros/Cons.

Allen S. Ho MD is Associate Professor of Surgery, Director of the Head and Neck Cancer Program, and Co-Director of the Thyroid Cancer Program at Cedars-Sinai Medical Center. As a fellowship-trained head and neck surgeon. His practice focuses on the treatment of head and neck tumors, including HPV(+) throat cancers and thyroid malignancies. He leads the multidisciplinary Cedars-Sinai Head and Neck Tumor Board, which provides consensus management options for complex, advanced cases. Dr. Ho’s research interests are highly integrated into his clinical practice. His current efforts lie in cancer proteomics, HPV(+) oropharyngeal cancer pathogenesis, and thyroid cancer molecular assays. Dr. Ho has published as lead author in journals that include Nature Genetics, JCO, JAMA Oncology, and Thyroid, and is Editor of the textbook Multidisciplinary Care of the Head and Neck Cancer Patient (Springer 2018). Dr. Ho serves on national committees within the AHNS and ATA, and leads a national trial on thyroid cancer active surveillance (ClinicalTrials.gov ID: NCT02609685). He maintains expertise in transoral robotic surgery (TORS), minimally invasive thyroidectomy approaches, and nerve preservation techniques. Dr. Ho’s overarching aim is to partner with patients to optimize treatment and provide compassionate, exceptional care. In this interview — a discussion about Dr. Ho’s research; Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review. Topics include: prostate and thyroid cancer parallels prostate cancer and practical acceptance of active surveillance randomized and followed patients through true active surveillance overall survival, comparing thyroid and prostrate cancer tolerance of risk Older versus younger patient priorities Younger patient  thought process Weighing quality of life and risk Hypothyroidism, parathyroidism, laryngeal nerve risk in thyroidectomy… asymptomatic patients being made symptomatic due to treatment Physicians have embraced active surveillance for prostate cancer more than thyroid The patient leans on physician for guidance The Finland study: 17M in U.S. have thyroid cancer Extrapolation — Patients who die of other conditions, in autopsies very small thyroid cancers found in 36% of patients A lot of small cancers that need not be diagnosed The physicians perspective and influencing the active surveillance decision Shared decision making process Terminology… some people choose active surveillance even when nodule is greater than 2cm Jury is still out on what is considered safe size Size and lymph node spread is still being defined Moving away from Gleason system Some cancers are aggressive Some cancers are slow and not lethal Incidental cancers The word cancer or the c word… and shifting away from fear Radiology guidelines The Cedars Sinai active surveillance program 50% of patients who are offered surveillance accept it… which mirrors Japan Alienation of active surveillance patients Anxious, calm, and risk and prioritize risks of surgery  Thyroid cancer tends to strike younger patients.  Prostrate cancer tends to be older. Prostrate cancer may not improve survival Surgery in thyroid versus prostate is safer Radiation ad toxicity NOTES Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review 50: Regarding Thyroid Cancer, Are You a Minimalist or a Maximalist? with Dr. Michael Tuttle from Sloan Kettering 89: Your Patient ‘Type’ May Determine Your Thyroid Cancer Treatment → Dr. Michael Tuttle from Sloan Kettering 77: Broadway Performer Says No to Thyroid Cancer Surgery → Surveillance Instead 87: Is There a Stigma to Choosing Active Surveillance? → Dr. Louise Davies from The Dartmouth Institute Vigilancia activa en el tratamiento del microcarcinoma de tiroides. Dr. Allen Ho

Dr. Allen Ho is a fellowship-trained head and neck surgeon who focuses on head and neck tumors, including HPV(+) throat cancers and thyroid malignancies. As director of the Head and Neck Cancer Program and co-director of the Thyroid Cancer Program, he leads the multidisciplinary Cedars-Sinai Head and Neck Tumor Board, which provides consensus management options for complex, advanced cases. Ho’s research interests are highly integrated into his clinical practice. His current efforts lie in cancer proteomics, HPV(+) oropharyngeal cancer pathogenesis, and thyroid cancer molecular assays. He has presented his research at AACR, ASCO, AHNS, and ATA, and has published extensively as lead author in journals that include Nature Genetics, Journal of Clinical Oncology, Cancer, and Thyroid. Ho serves on national committees within the ATA and AHNS, and is principal investigator of a national trial on micropapillary thyroid cancer active surveillance (ClinicalTrials.gov ID: NCT02609685). He maintains expertise in transoral robotic surgery (TORS), minimally invasive thyroidectomy approaches, and nerve preservation techniques. Ho’s overarching mission is to partner with patients to optimize treatment and provide compassionate, exceptional care. Weighing treatment options for thyroid cancer, with deep consideration for the patient’s lifestyle, could become the new norm in assessing whether surgery is the best path.  Dr. Allen Ho states, “if a patient is a ballerina or an opera singer, or any other profession that could be jeopardized due to undesired consequences of thyroid cancer surgery, then the best treatment path maybe active surveillance.”  Undesired consequences of thyroid cancer surgery could be vocal cord paralysis, damage to the parathyroid glands resulting in calcium deficiencies, excessive bleeding or formation of a major blood clot in the neck, shoulder nerve damage, numbness, wound infection, and mental impairment due to hypothyroid-like symptoms.  Or in the case of a ballerina, undesired scarring could jeopardize a career.    The above risks occur in approximately 10% of thyroid cancer surgeries.  Although, some thyroid cancer treatment centers have a much more reduced incidence of undesired consequences, while others much higher.  In order to address the above and remove the risk of thyroid cancer surgery, Cedars-Sinai has become the first west coast hospital to launch an active surveillance study as optional treatment for thyroid cancer.  The study includes 200 patients from across the country who have chosen the wait and see approach rather than hurry into a surgery that could result in undesired, major life changes.   By waiting, this means these patients will dodge the need to take daily hormone replacement medication for the rest of their lives as the result of a thyroidectomy.  Other active surveillance research Although this is the first study for active surveillance on the west coast, other studies are ongoing, including Sloan Kettering as directed by Dr. Tuttle, Kuma Hospital in Kobe as directed by Dr. Miyauchi, and the Dartmouth Institute as directed by Dr. Louise Davies. The team Dr. Ho says the “de-escalating” of treatment for thyroid cancer will become the new trend.  The active surveillance thyroid cancer team at Cedars-Sinai is orchestrated to the patient’s needs, and includes the pathologist, endocrinologist, and surgeon. NOTES Allen Ho, MD Active Surveillance of Thyroid Cancer Under Study 22: Avoiding Thyroid Cancer Surgery, Depending on the Size with Dr. Miyauchi from Kuma Hospital in Kobe, Japan 21: Diagnosed with Thyroid Cancer and You Say No to Surgery with Dr. Louise Davies

Prof Kraus talks to ecancertv at IAOO 2015 about the work of the American Head and Neck society (AHNS) and their advocacy for patients with head and neck cancer. He also discusses the emergence of Human papillomavirus (HPV).

Weighing treatment options for thyroid cancer, with deep consideration for the patient’s lifestyle, could become the new norm in assessing whether surgery is the best path.  Dr. Allen Ho states, “if a patient is a ballerina or an opera singer, or any other profession that could be jeopardized due to undesired consequences of thyroid cancer surgery, then the best treatment path maybe active surveillance.”  Undesired consequences of thyroid cancer surgery could be vocal cord paralysis, damage to the parathyroid glands resulting in calcium deficiencies, excessive bleeding or formation of a major blood clot in the neck, shoulder nerve damage, numbness, wound infection, and mental impairment due to hypothyroid-like symptoms.  Or in the case of a ballerina, undesired scarring could jeopardize a career.    The above risks occur in approximately 10% of thyroid cancer surgeries.  Although, some thyroid cancer treatment centers have a much more reduced incidence of undesired consequences, while others much higher.  In order to address the above and remove the risk of thyroid cancer surgery, Cedars-Sinai has become the first west coast hospital to launch an active surveillance study as optional treatment for thyroid cancer.  The study includes 200 patients from across the country who have chosen the wait and see approach rather than hurry into a surgery that could result in undesired, major life changes.   By waiting, this means these patients will dodge the need to take daily hormone replacement medication for the rest of their lives as the result of a thyroidectomy.  Other active surveillance research Although this is the first study for active surveillance on the west coast, other studies are ongoing, including Sloan Kettering as directed by Dr. Tuttle, Kuma Hospital in Kobe as directed by Dr. Miyauchi, and the Dartmouth Institute as directed by Dr. Louise Davies. The team Dr. Ho says the “de-escalating” of treatment for thyroid cancer will become the new trend.  The active surveillance thyroid cancer team at Cedars-Sinai is orchestrated to the patient’s needs, and includes the pathologist, endocrinologist, and surgeon.   About Dr. Allen Ho Allen Ho, MD, is a fellowship-trained head and neck surgeon who focuses on head and neck tumors, including HPV(+) throat cancers and thyroid malignancies. As director of the Head and Neck Cancer Program and co-director of the Thyroid Cancer Program, he leads the multidisciplinary Cedars-Sinai Head and Neck Tumor Board, which provides consensus management options for complex, advanced cases. Ho's research interests are highly integrated into his clinical practice. His current efforts lie in cancer proteomics, HPV(+) oropharyngeal cancer pathogenesis, and thyroid cancer molecular assays. He has presented his research at AACR, ASCO, AHNS, and ATA, and has published extensively as lead author in journals that include Nature Genetics, Journal of Clinical Oncology, Cancer, and Thyroid. Ho serves on national committees within the ATA and AHNS, and is principal investigator of a national trial on micropapillary thyroid cancer active surveillance (ClinicalTrials.gov ID: NCT02609685). He maintains expertise in transoral robotic surgery (TORS), minimally invasive thyroidectomy approaches, and nerve preservation techniques. Ho’s overarching mission is to partner with patients to optimize treatment and provide compassionate, exceptional care. NOTES American Thyroid Association Cedars-Sinai clinical trial MSKCC thyroid cancer active surveillance THYCA Support Group   Active Surveillance of Thyroid Cancer Under Study